Carbamoyl phenylalaninol compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-11149000-B2
Application number	US-202016891464-A
Country	US
Kind code	B2
Filing date	Jun 3, 2020
Priority date	Oct 6, 2016
Publication date	Oct 19, 2021
Grant date	Oct 19, 2021

Abstract

The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.

First claim

What is claimed is:

1. A method of treating narcolepsy, cataplexy, drug addiction, sexual dysfunction, fibromyalgia, restless legs syndrome, depression, bipolar disorder, or obesity in a subject in need thereof, or promoting smoking cessation in a subject in need thereof, comprising administering to subject a compound of Formula

wherein
R is optionally substituted lower alkyl of 1 to 8 carbon atoms, halogen, optionally substituted alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, cyano, trifluoromethyl, or optionally substituted thioalkoxy containing 1 to 3 carbon atoms;
x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R 1 , R 2 , and R 3 are independently hydrogen, optionally substituted lower alkyl of 1 to 8 carbon atoms, optionally substituted aryl, optionally substituted arylalkl, or optionally substituted cycloalkyl of 3 to 7 carbon atoms; or
R 2 and R 3 can be joined to form a 5 to 7-membered heterocycle optionally substituted with a member selected from the group consisting of alkyl and aryl groups, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom;
or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is a compound of Formula II:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is compound 1:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is compound 2:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , comprising administering a composition comprising the compound.

6. The method of claim 1 , comprising administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

7. The method of claim 6 , wherein the composition is a dosage form.

8. The method of claim 7 , wherein the composition is an immediate release oral dosage form.

9. The method of claim 8 , wherein the composition is a tablet or a capsule.

Assignees

• Jazz Pharmaceuticals Ireland Ltd

Inventors

• Hurley Fionn
• Carter Lawrence Patrick

Classifications

• A61P25/20

  Hypnotics; Sedatives · CPC title

• C07C275/60 Primary

  Y being an oxygen atom, e.g. allophanic acids · CPC title

• A61P25/24

  Antidepressants · CPC title

• C07C2601/16

  the ring being unsaturated · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title